New insight into the binding mode of peptide ligands at urotensin-II receptor: Structure- activity relationships study on P5U and urantide

Journal of Medicinal Chemistry

Volumn 52, Issue 13, 2009, Pages 3927-3940

  Grieco, Paolo ^a   Carotenuto, Alfonso ^a   Campiglia, Pietro ^d   Gomez Monterrey, Isabel ^a   Auriemma, Luigia ^a   Sala, Marina ^d   Marcozzi, Cristina ^a   Bianca, Roberta D'Emmanuele Di Villa ^a   Brancaccio, Diego ^a   Rovero, Paolo ^b   Santicioli, Paolo ^c   Meini, Stefania ^c   Maggi, Carlo A ^c   Novellino, Ettore ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Menarini Ricerche ^*  (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ASPARTYLCYCLO(PHENYLALANYLPHENYLALANYLTRYPTOPHYLLYSYLTYROSYLCYSTEINYL)VALYLHYDROXIDE; CYCLOPEPTIDE; UNCLASSIFIED DRUG; URANTIDE; URANTIDE DERIVATIVE; UROTENSIN II;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

CELL LINE; COMPUTER SIMULATION; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; UROTENSINS;

EID: 67649974141     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900148c     Document Type: Article

References (72)

1. Pearson, D.; Shively, J. E.; Clark, B. R.; Geschwind, I. I.; Barkley, M.; Nishioka, R. S.; Bern, H. A. Urotensin II: A Somatostain-Like Peptide in the Caudal Neurosecretory System of Fishes. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5021-5024.
2. Conlon, J. M.; O'Harte, F.; Smith, D. D.; Tonon, M. C.; Vaudry, H. Isolation and Primary Structure of Urotensin II From the Brain of a Tetrapod, the Frog Rana Ridibunda. Biochem. Biophys. Res. Commun. 1992, 188, 578-583.
3. Beauvillain, J. C.; Conlon, J. M.; Bern, H. A.; Vaudry, H. Cloning of the cDNA Encoding the Urotensin II Precursor in Frog and Human Reveals Intense Expression of the Urotensin II Gene in Motoneurons of the Spinal Cord. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15803-15808.
4. Coulouarn, Y.; Jegou, S.; Tostivint, H.; Vaudry, H.; Lihrmann, I. Cloning, Sequence Analysis and Tissue Distribution of the Mouse and Rat Urotensin II Precursors. FEBS Lett. 1999, 457, 28-32.
5. Mori, M.; Sugo, T.; Abe, M.; Shimomura, Y.; Kurihara, M.; Kitada, C.; Kikuchi, K.; Shintani, Y.; Kurokawa, T.; Onda, H.; Nishimura, O.; Fujino, M. Urotensin II is the Endogenous Ligand of a G-protein Coupled Orphan Receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 1999, 265, 123-129.
6. Elshourbagy, N. A.; Douglas, S. A.; Shabon, U.; Harrison, S.; Duddy, G.; Sechler, J. L.; Ao, Z.; Maleef, B. E.; Naselsky, D.; Disa, J.; Aiyar, N. V. Molecular and Pharmacological Characterization of Genes Encoding Urotensin II-Related Peptides and their Cognate G-Protein Coupled Receptors from the Mouse and Monkey. Br. J. Pharmacol. 2002, 136, 9-22.
7. Ames, R. S.; Sarau, H. M.; Chambers, J. K.; Willette, R. N.; Aiyar, R. V.; Romanic, A. M.; Louden, C. S.; Foley, J. J.; Sauermelch, C. F.; Coatney, R. W.; Ao, Z.; Disa, J.; Holmes, S. D.; Stadel, J. M.; Martin, J. D.; Liu, W.-S.; Glover, G. I.; Wilson, S.; McNutty, D. E.; Ellis, C. E.; Eishourbagy, N. A.; Shabon, U.; Trill, J. J.; Hay, D. V. P.; Ohlstein, E. H.; Bergsma, D. J.; Douglas, S. A. Human Urotensin-II Is a Potent Vasoconstrictor and Agonist for the Orphan Receptor GPR14. Nature 1999, 401, 282-286.
8. Sugo, T.; Murakami, Y.; Shimomura, Y.; Harada, M.; Abe, M.; Ishibashi, Y.; Kitada, C.; Miyajima, N.; Suzuki, N.; Mori, M.; Fujino, M. Identification of Urotensin II-Related Peptide as the Urotensin II Immunoreactive Molecule in the Rat Brain. Biochem. Biophys. Res. Commun. 2003, 310, 860-868.
9. Chatenet, D.; Dubessy, C.; Leprince, J.; Boularan, C.; Carlier, L.; Segalas-Milazzo, I.; Guilhaudis, L.; Oulyadi, H.; Davoust, D.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Tonon, M. C.; Lihrmann, I.; Pacaud, P.; Vaudry, H. Structure-Activity Relationships and Structural Conformation of a Novel Urotensin II-Related Peptide. Peptides 2004, 25, 1819-1830.
10. Chartrel, N.; Conlon, J. M.; Collin, F.; Braun, B.; Waugh, D.; Vallarino, M.; Lahrichi, S. L.; Rivier, J. E.; Vaudry, H. Urotensin II in the Central Nervous System of the Frog Rana ridibunda: Immunohistochemical Localization and Biochemical Characterization. J. Comput. Neurol. 1996, 364, 324-339.
11. Coulouarn, Y.; Fernex, C.; Jegou, S.; Henderson, C. E.; Vaudry, H.; Lihrmann, I. Specific Expression of the Urotensin II Gene in Sacral Motoneurons of Developing Rat Spinal Cord. Mech. Dev. 2001, 101, 187-190.
12. Pelletier, G.; Lihrmann, I.; Vaudry, H. Role of Androgens in the Regulation of Urotensin II Precursor mRNA Expression in the Rat Brainstem and Spinal Cord. Neuroscience 2002, 115, 525-532.
13. Pelletier, G.; Lihrmann, I.; Dubessy, C.; Luu-The, V.; Vaudry, H.; Labrie, F. Androgenic Down-Regulation of Urotensin II Precursor, Urotensin II-Related Peptide Precursor and Androgen Receptor mRNA in the Mouse Spinal Cord. Neuroscience 2005, 132, 689-696.
14. Novellino, E.; Grieco, P.; Caraglia, M.; Budillon, A.; Franco, R.; Addeo, S. R. Peptidic and Nonpeptidic Ligands for Immunodetection of Urotensin-II Receptor PCT Int. Appl. WO 2008095995, 2008; 21 pp.
15. Maguire, J. J.; Davenport, A. P. Is Urotensin-II the New Endothelin? Br. J. Pharmacol. 2002, 137, 579-588.
16. Douglas, S. A.; Ohlstein, E. H. Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardivascular Diseases. Trends Cardiovasc. Med. 2000, 10, 229-237.
17. Douglas, S. A. Human Urotensin-II as a Novel Cardiovascular Target: "Heart" of the Matter or Simply a Fish "Tail"? Curr. Opin. Pharmacol. 2003, 3, 159-167.
18. Silvestre, R. A.; Egido, E. M.; Hernandez, R.; Leprince, J.; Chatenet, D.; Tollemer, H.; Chartrel, N.; Vaudry, H.; Marco, J. Urotensin-II is Present in Pancreatic Extracts and Inhibits Insulin Release in the Perfused Rat Pancreas. Eur. J. Endocrinol. 2004, 151, 803-809.
19. Djordjevic, T.; Belaiba, R. S.; Bonello, S.; Pfeilschifter, J.; Hess, J.; Gorlach, A. Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 519-25.
20. Matsumoto, Y.; Abe, M.; Watanabe, T.; Adachi, Y.; Yano, T.; Takahashi, H.; Sugo, T.; Mori, M.; Kitada, C.; Kurokawa, T.; Fujino, M. Intracerebroventricular Administration of Urotensin II Promotes Anxiogenic-Like Behaviors in Rodents. Neurosci. Lett. 2004, 358, 99-102.
21. Itoh, H.; McMaster, D.; Lederis, K. Functional Receptors for Fish Neuropeptide Urotensin II in Major Rat Arteries. Eur. J. Pharmacol. 1988, 149, 61-66.
22. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Magnetic Resonance Studies on Urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
23. Kinney, W. A.; Almond, H. R.; Qi, J.; Smith, C. E.; Santulli, R. J.; de Garavilla, L.; Andrade-Gordon, P.; Cho, D. S.; Everson, A. M.; Feinstein, M. A.; Leung, P. A.; Maryanoff, B. E. Structure-Function Analysis of Urotensin II and its Use in the Construction of a Ligand-Receptor Working Model. Angew. Chem., Int. Ed. 2002, 41, 2940-2944.
24. Brkovic, A.; Hattenberger, A.; Kostenis, E.; Klabunde, T.; Flohr, S.; Kurz, M.; Bourgault, S.; Fournier, A. Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay. J. Pharmacol. Exp. Ther. 2003, 306, 1200-1209.
25. Labarrere, P.; Chatenet, D.; Leprince, J.; Marionneau, C.; Loirand, G.; Tonon, M. C.; Dubessy, C.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Calas, B.; Pacaud, P.; Vaudry, H. Structure-Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction. J. Enzyme Inhib. Med. Chem. 2003, 18, 77-88.
26. Coy, D. H.; Rossowski, W. J.; Cheng, B. L.; Taylor, J. E. Structural Requirements at the N-Terminus of Urotensin II Octapeptides. Peptides 2002, 23, 2259-2264.
27. Lescot, E.; Bureau, R.; Rault, S. Nonpeptide Urotensin-II Receptor Agonists and Antagonists: Review and Structure-Activity Relationships. Peptides 2007, 29, 680-690.
28. Hruby, V. J. Designing Peptide Receptors Agonists and Antagonists. Nat. Rev. Drug Discovery 2002, 1, 847-858.
29. Carotenuto, A.; Grieco, P.; Rovero, P.; Novellino, E. Urotensin-II Receptor Antagonists. Curr. Med. Chem. 2006, 13, 267-275.
30. Grieco, P.; Carotenuto, A.; Campiglia, P.; Zampelli, E.; Patacchini, R.; Maggi, C. A.; Novellino, E.; Rovero, P. A New Potent Urotensin-II Receptor Peptide Agonist Containing a Pen Residue at Disulfide Bridge. J. Med. Chem. 2002, 45, 4391-4394.
31. Patacchini, R.; Santicioli, P.; Giuliani, S.; Grieco, P.; Novellino, E.; Rovero, P.; Maggi, C. A. Urantide: an Ultrapotent Urotensin II Antagonist Peptide in the Rat Aorta. Br. J. Pharmacol. 2003, 140, 1155-1158.
32. Camarda, V.; Song, W.; Marzola, E.; Spagnol, M.; Guerrini, R.; Salvatori, S.; Regoli, D.; Thompson, J. P.; Rowbotham, D. J.; Behm, D. J.; Douglas, S. A.; Calo', G.; Lambert, D. G. Urantide Mimics Urotensin-II Induced Calcium Release in Cells Expressing Recombinant UT Receptors. Eur. J. Pharmacol. 2004, 498, 83-86.
33. Grieco, P.; Carotenuto, A.; Campiglia, P.; Marinelli, L.; Lama, T.; Patacchini, R.; Santicioli, P.; Maggi, C. A.; Rovero, P.; Novellino, E. Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity. J. Med. Chem. 2005, 48, 7290-7297.
34. Carotenuto, A.; Grieco, P.; Campiglia, P.; Novellino, E.; Rovero, P. Unraveling the Active Conformation of Urotensin II. J. Med. Chem. 2004, 47, 1652-1661.
35. Stewart J. M.; Young J. D. Solid Phase Peptide Synthesis, 2nded.; Pierce Chemical: Rockford, IL, 1984.
36. Wüthrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons, Inc: New York, 1986.
37. (a) Piantini, U.; Sorensen, O. W.; Ernst, R. R. Multiple Quantum Filters for Elucidating NMR Coupling Network. J. Am. Chem. Soc. 1982, 104, 6800-6801.
38. 1H Spin-Spin Coupling Constants in Proteins. Biochem. Biophys. Res. Commun. 1983, 113, 967-974.
39. Braunschweiler, L.; Ernst, R. R. Coherence Transfer by Isotropic Mixing: Application to Proton Correlation Spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
40. Jenner, J.; Meyer, B. H.; Bachman, P.; Ernst, R. R. Investigation of Exchange Processes by Two-Dimensional NMR Spectroscopy. J. Chem. Phys. 1979, 71, 4546-4553.
41. Bartels, C.; Xia, T.; Billeter, M.; Guentert, P.; Wüthrich, K. The Program XEASY for Computer-Supported NMR Spectral Analysis of Biological Macromolecules. J. Biomol. NMR 1995, 6, 1-10.
42. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, T. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
43. Lavecchia, A.; Cosconati, S.; Novellino, E. Architecture of the Human Urotensin II Receptor: Comparison of the Binding Domains of the Peptide and Nonpeptide Urotensin II Agonists. J. Med. Chem. 2005, 48, 2480-2492.
44. Holleran, B. J.; Beaulieu, M. E.; Proulx, C. D.; Lavigne, P.; Escher, E.; Leduc, R. Photolabelling the Urotensin II Receptor Reveals Distinct Agonist- and Partial-Agonist-Binding Sites. Biochem. J. 2007, 402, 51-61.
45. (a) Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated Docking of Flexible Ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
46. (b) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
47. (c) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. Software News and Update. A Semiempirical Free Energy Force Field with Charge-Based Desolvation. J. Comput. Chem. 2007, 28, 1145-1152.
48. Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H.; Mosberg, H. I. Complex of an Active μ-Opioid Receptor with a Cyclic Peptide Agonist Modeled from Experimental Constraints. Biochemistry 2004, 43, 15796-15810. http://mosberglab.phar.umich.edu/resources/models/OPSD- BOVIN-AD.pdb.
49. Marzola, E.; Camarda, V.; Batuwangala, M.; Lambert, D. G.; Caló, G.; Guerrini, R.; Trapella, C.; Regoli, D.; Tomatis, R.; Salvadori, S. Structure-Activity Relationship Study of Position 4 in the Urotensin-II Receptor Ligand U-II(4-11). Peptides 2008, 29, 674-679.
50. Moroder, L.; Romano, R.; Guba, W.; Mierke, D. F.; Kessler, H.; Delporte, C.; Winand, J.; Christophe, J. New Evidence for a Membrane Bound Pathway in Hormone Receptor Binding. Biochemistry 1993, 32, 13551-13559.
51. Sargent, D. F.; Schwyzer, R. Membrane Lipid Phase as Catalyst for Peptide-Receptor Interactions. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 5774-5778.
52. Lescot, E.; Sopkova-de Oliveira Santos, J.; Colloc'h, N.; Rodrigo, J.; Milazzo-Segalas, I.; Bureau, R.; Rault, S. Three-Dimensional Model of the Human Urotensin-II Receptor: Docking of Human Urotensin-II and Nonpeptide Antagonists in the Binding Site and Comparison with an Antagonist Pharmacophore Model. Proteins 2008, 73, 173-184.
53. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-Resolution Crystal Structure of an Engineered Human Beta2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318, 1258-1265.
54. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a Beta1-Adrenergic G-Protein-Coupled Receptor. Nature 2008, 454, 486-491.
55. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 Angstrom Crystal Structure of a Human A2a Adenosine Receptor Bound to an Antagonist. Science 2008, 322, 1211-1217.
56. Boivin, S.; Guilhaudis, L.; Milazzo, I.; Oulyadi, H.; Davoust, D.; Fournier, A. Characterization of Urotensin-II Receptor Structural Domains Involved in the Recognition of U-II, URP, and Urantide. Biochemistry 2006, 45, 5993-6002.
57. Boivin, S.; Ségalas-Milazzo, I.; Guilhaudis, L.; Oulyadi, H.; Fournier, A.; Davoust, D. Solution Structure of Urotensin-II receptor Extracellular Loop III and Characterization of its Interaction with Urotensin-II. Peptides 2008, 29, 700-710.
58. Boucard, A. A.; Sauvé, S. S.; Guillemette, G.; Escher, E.; Leduc, R. Photolabelling the Rat Urotensin II/GPR14 Receptor Identifies a Ligand-Binding Site in the Fourth Transmembrane Domain. Biochem. J. 2003, 370, 829-838.
59. Guerrini, R.; Camarda, V.; Marzola, E.; Arduin, M.; Calo, G.; Spagnol, M.; Rizzi, A.; Salvatori, S.; Regoli, D. Structure-Activity Relationship Study on Human Urotensin II. J. Pept. Sci. 2005, 11, 85-90.
60. Camarda, V.; Spagnol, M.; Song, W.; Vergura, R.; Roth, A. L.; Thompson, J. P.; Rowbotham, D. J.; Guerrini, R.; Marzola, E.; Salvatori, S.; Cavanni, P.; Regoli, D.; Douglas, S. A.; Lambert, D. G.; Calò, G. In Vitro and In Vivo Pharmacological Characterization of the Novel UT Receptor Ligand [Pen5, DTrp7, Dab8]Urotensin II(4-11) (UFP-803). Br. J. Pharmacol. 2006, 147, 92-100.
61. Misika, A.; Hruby, V. J. Optimization of Disulfide Bond Formation. Pol. J. Chem. 1994, 68, 893-899.
62. (a) Kenakin, T. P. Competitive antagonism. In Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed.; Lippincott-Raven Press: Philadelphia, 1997; pp 331-373.
63. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
64. Hwang, T. L.; Shaka, A. J. Water Suppression that Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients. J. Magn. Reson. 1995, 112, 275-279.
65. Mueller, L. P. E. COSY, a Simple Alternative to E. COSY. J. Magn. Reson. 1987, 72, 191-196.
66. States, D. J.; Haberkorn, R. A.; Ruben, D. J. A Two-Dimensional Nuclear Overhauser Experiment with Pure Absorption Phase in Four Quadrants. J. Magn. Reson. 1982, 48, 286-292.
67. Guntert, P.; Mumenthaler, C.; Wüthrich, K. Torsion Angle Dynamics for NMR Structure Calculation with the New Program, DYANA. J. Mol. Biol. 1997, 273, 283-298.
68. Koradi, R.; Billeter, M.; Wüthrich, K. MOLMOL: A Program for Display and Analysis of Macromolecular Structures. J. Mol. Graphics 1996, 14, 51-55.
69. Maple, J.; Dinur, U.; Hagler, A. T. Derivation of Force Fields for Molecular Mechanics and Dynamics from Ab Initio Energy Surface. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.
70. (a) Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A Program to Check the Stereochemical Quality of Protein Structures. J. Appl. Crystallogr. 1993, 26, 283-291.
71. (b) Morris, A. L.; MacArthur, M. W.; Hutchinson, E. G.; Thornton, J. M. Stereochemical Quality of Protein Structure Coordinates. Proteins 1992, 12, 345-364.
72. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605-1612.